| 000 | 01814 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250511181346.0 | ||
| 264 | 0 | _c19921113 | |
| 008 | 199211s 0 0 eng d | ||
| 022 | _a0022-3476 | ||
| 024 | 7 |
_a10.1016/s0022-3476(05)81161-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHusson, R N | |
| 245 | 0 | 0 |
_aPhase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection. _h[electronic resource] |
| 260 |
_bThe Journal of pediatrics _cOct 1992 |
||
| 300 |
_a627-33 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xdrug therapy |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntigens, Viral _xblood |
| 650 | 0 | 4 |
_aCD4 Antigens _xadministration & dosage |
| 650 | 0 | 4 | _aCD4-Positive T-Lymphocytes |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aDidanosine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aLeukocyte Count |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aChung, Y | |
| 700 | 1 | _aMordenti, J | |
| 700 | 1 | _aButler, K M | |
| 700 | 1 | _aChen, S | |
| 700 | 1 | _aDuliege, A M | |
| 700 | 1 | _aBrouwers, P | |
| 700 | 1 | _aJarosinski, P | |
| 700 | 1 | _aMueller, B U | |
| 700 | 1 | _aAmmann, A | |
| 773 | 0 |
_tThe Journal of pediatrics _gvol. 121 _gno. 4 _gp. 627-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0022-3476(05)81161-8 _zAvailable from publisher's website |
| 999 |
_c1363622 _d1363622 |
||